Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease
<p>Abstract</p> <p/> <p>Mucopolysaccharidosis type II (MPS II) is a rare, life-limiting, X-linked recessive disease characterised by deficiency of the lysosomal enzyme iduronate-2-sulfatase. Consequent accumulation of glycosaminoglycans leads to pathological changes in multip...
Main Authors: | Scarpa Maurizio, Almássy Zsuzsanna, Beck Michael, Bodamer Olaf, Bruce Iain A, De Meirleir Linda, Guffon Nathalie, Guillén-Navarro Encarna, Hensman Pauline, Jones Simon, Kamin Wolfgang, Kampmann Christoph, Lampe Christina, Lavery Christine A, Leão Teles Elisa, Link Bianca, Lund Allan M, Malm Gunilla, Pitz Susanne, Rothera Michael, Stewart Catherine, Tylki-Szymańska Anna, van der Ploeg Ans, Walker Robert, Zeman Jiri, Wraith James E |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2011-11-01
|
Series: | Orphanet Journal of Rare Diseases |
Online Access: | http://www.ojrd.com/content/6/1/72 |
Similar Items
-
Bone metabolism in patients with mucopolysaccharidosis type II
by: Zbigniew Żuber, et al.
Published: (2014-11-01) -
Diagnosis and Management of Mucopolysaccharidosis Type II (Hunter Syndrome) in Poland
by: Zbigniew Żuber, et al.
Published: (2023-06-01) -
RETRACTED: An Innovative Tool for Evidence-Based, Personalized Treatment Trials in Mucopolysaccharidosis
by: Anna-Maria Wiesinger, et al.
Published: (2023-05-01) -
Comparison of Rebound Tonometry, Perkins Applanation Tonometry and Ocular Response Analyser in Mucopolysaccharidosis Patients.
by: Joanna Wasielica-Poslednik, et al.
Published: (2015-01-01) -
RETRACTED: Wiesinger et al. An Innovative Tool for Evidence-Based, Personalized Treatment Trials in Mucopolysaccharidosis. <i>Pharmaceutics</i> 2023, <i>15</i>, 1565
by: Anna-Maria Wiesinger, et al.
Published: (2023-11-01)